GlobeNewswire Inc | Nov 9, 2021 04:01PM EST

November 09, 2021

SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.(Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, todayannouncedthat Arthur T. Sands, M.D., Ph.D., Nurixs president and chief executive officer, will participate in fireside chats at the following conferences in November:

-- Stifel 2021 Virtual Healthcare ConferenceTuesday, November 16th, at 3:20-3:50 PM EST -- Piper Sandler 33rd Annual Virtual Healthcare ConferenceTuesday, November 30th, at 11:30-11:55 AM EST

The discussions will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. Archived copies of the webcasts will be available on the Nurix website for approximately 30 days after the event.

About Nurix Therapeutics, Inc.Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurixs extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurixs drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurixs wholly owned pipeline includes targeted protein degraders of Brutons tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.

Contacts:

Investors: Media:Jason Kantor, Ph.D. Elizabeth Wolffe, Ph.D.Nurix Therapeutics, Inc. Wheelhouse Life Science Advisorsjkantor@nurixtx.com lwolffe@wheelhouselsa.com